Around 25% of the world's population is estimated to be affected by fatty liver disease(1) but as it's a 'silent disease' most people are unaware of the issue(2). Over time it can lead to cirrhosis, liver cancer and liver failure(1).
A picture is gradually building of the types of people who are more at risk of fatty liver disease(3):
• 8 out of 10 are obese
• 5 out of 10 have type 2 diabetes
• 7 out of 10 have high blood pressure
We're currently looking for people who could take part in our clinical research trial in fatty liver disease. Would you consider joining us?
NASH (nonalcoholic steatohepatitis) is an advanced form of fatty liver disease where there is inflammation and damage to the liver.
The purpose of the C3711005 clinical research study is to evaluate the benefits on liver steatosis of two oral investigational drugs when given together in a range of dosage regimens and assess any increase in triglycerides (a type of fat found in the blood).
Liver fat and stiffness will be assessed via ultrasound and MRI scans during the screening and run-in phase and at the end of the treatment period. The study has a 6-week treatment phase where participants are required to take 3 tablets twice a day.
Your health will be monitored throughout study with assessments including physical examinations, alcohol intake questionnaires, blood and urine tests, and ECGs. While there is no absolute guarantee that you will receive any benefit from the study drugs you receive, you will be helping to advance medical knowledge of NASH with fibrosis and will receive support from the expert medical team throughout the study.
1. Younossi ZM. J Hepatol 2019; 70: 531-544.
2. Chopra S. Patient education: Nonalcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) (Beyond the Basics). UpToDate.com. Available at:
https://www.uptodate.com/contents/nonalcoholic-fatty-liver-disease-nafld-including-nonalcoholic-steatohepatitis-nash-beyond-the-basics Accessed July 2020.
3. Younossi ZM et al. Nat Rev Gastroenterol Hepatol 2018; 15(1): 11-20.